MaxCyte’s H1 2016 trading update shows trading in the year to date is in line with expectations for the full year. H1 revenue is expected to be “not less than $5.4m”, an increase of over 30% on H1 2015. Performance remains strong across both divisions. We make no changes to our forecasts, but given the strong performance in H1, have increasing confidence in our FY estimates. We reiterate our BUY recommendation and 170p price target.
